CAS
CRSP icon

Coppell Advisory Solutions’s CRISPR Therapeutics CRSP Stock Holding History

Coppell Advisory Solutions’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$20.1K Buy
321
+301
+1,505% +$16.6K ﹤0.01% 738
2023
Q3 		$813 Hold
20
– – ﹤0.01% 955
2023
Q2 		$1.14K Buy
+20
New +$1.14K ﹤0.01% 1121
2023
Q1 		– Sell
-20
Closed -$813 – 382
2022
Q4 		$813 Buy
+20
New +$1.06K ﹤0.01% 957

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Coppell Advisory Solutions's CRSP Position: Q4 2023 in Review

Coppell Advisory Solutions increased its CRISPR Therapeutics (CRSP) stake by 1,505% in Q4 2023, buying an estimated $16.6K and bringing the position to 321 shares worth $20.1K. The position accounts for ﹤0.01% of the portfolio, ranked #738.

Coppell Advisory Solutions first reported a position in CRSP in Q4 2022 and has held it in 4 quarters since. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

  • Coppell Advisory Solutions held 321 shares of CRISPR Therapeutics worth $20.1K as of Q4 2023.
  • Coppell Advisory Solutions bought 301 CRISPR Therapeutics shares in Q4 2023, an estimated $16.6K.
  • CRISPR Therapeutics made up ﹤0.01% of Coppell Advisory Solutions's portfolio in Q4 2023, its #738 holding.
  • Coppell Advisory Solutions first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 4 quarters since.
  • 472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Coppell Advisory Solutions's 13F filing for Q4 2023, filed 14 Feb 2024.